Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Provided By GlobeNewswire
Last update: Mar 6, 2025
PARSIPPANY, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on March 4, 2025 to six new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.
Read more at globenewswire.comNASDAQ:PCRX (4/22/2025, 1:31:09 PM)
25.22
-0.68 (-2.63%)
Find more stocks in the Stock Screener
PCRX Latest News and Analysis
7 days ago - ChartmillPACIRA BIOSCIENCES INC (NASDAQ:PCRX), a growth stock which is not overvalued.Discover PACIRA BIOSCIENCES INC, an undervalued growth gem. NASDAQ:PCRX is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
15 days ago - ChartmillWondering what's happening in today's after-hours session?The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today.
17 days ago - ChartmillPACIRA BIOSCIENCES INC (NASDAQ:PCRX) is an undervalued gem with solid fundamentals.PACIRA BIOSCIENCES INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:PCRX showcases decent financial health and profitability, coupled with an attractive price.
